Article: SmithKline Beecham's Bactroban(R) Nasal Shown to Decrease Risk of S. Aureus Nosocomial Infections in Surgical Patients.

New Study Suggests Role for Prophylaxis in Reducing Incidence of

Life-Threatening and Costly Infections

SAN FRANCISCO, April 19 /PRNewswire/ -- The pre-operative use of Bactroban(R) Nasal (mupirocin calcium ointment, 2%, SmithKline Beecham), a broad-spectrum, topical antibiotic, significantly decreases the risk of Staphylococcus aureus (S. aureus) nosocomial infections among surgical patients, according to a new study reported today at the annual meeting of the Society for Healthcare Epidemiologists of America. Patients treated pre-operatively with Bactroban Nasal (applied intranasally twice daily for up to five days) experienced 50 percent fewer ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!